Registered Members of Investor Village: Please make sure you are signed in to your Investor Village account to enjoy the full benefits of our service and avoid the MediaPass paywall. If the MediaPass offer page is blocking you, click the light blue "No thanks, take me back" link on the middle right side of the form to get to our home page where you can sign in by entering your Investor Village User Name and Password.
MediaPass subscribers: Please make sure you are logged in to your MediaPass subscription to bypass the paywall. You can do this by clicking the light blue "Already have a MediaPass account? Login here" link on the middle left side of the subscription offer form and then entering the email address and password you used when you first signed up with MediaPass.
For assistance call 888-222-7309 or email email@example.com
uniQure jumps after Chardan boosts price target to $175 from $100Chardan analyst Gbola Amusa raised his price target for uniQure (QURE) to $175 from $100 to reflect the company's opportunity in Huntington's disease. The stock in morning trading is up 4.5%, or $2.63, to $61.64. uniQure, a Chardan Top Pick for 2019, could be headed towards a $5B-$10B valuation as support emerges for what could be a "best-in-class, breakthrough" Huntington's disease franchise, Amusa tells investors in a research note. In the second half of 2019, uniQure is expected to make AMT-130 the first one-time gene theraphy to enter the clinic for Huntington's, the analyst adds. Following due diligence, Amusa now expects peak AMT-130 sales of $2.7B, 25% risk-adjusted, in 2026. While the market opportunity for Huntington's is potentially larger than that for Duchenne muscular dystrophy, uniQure does have some analogy to Sarepta Therapeutics (SRPT), which moved up 114% in 2018, Amusa writes. He keeps a Buy rating on uniQure shares.
Read more at: https://thefly.com/landingPageNews.php?id=2910535